Program
VLA15
A development code. Also written as “VLA15 with Alum” and “VLA15 without Alum”.
In Pfizer's pipeline, Prophylactic vaccine – protein subunit (Lyme Disease)
. Its studies are mostly in Lyme Disease, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 82 open or running | phase 3since Jul 5, 2022 | Dec 21, 2016 | Dec 4, 2026phase 3 · NCT07500506 |
- Named in Pfizer’s own pipeline as
PF-07307405
, phase 4, as of Nov 3, 2026 (source).
Also a collaborator on its studies: Valneva.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 21, 2016First study: phase 1 study in Lyme NeuroborreliosisFirst studyNCT03010228 · 179 enrolled · United States, Belgium
- Dec 6, 2018Phase 2 study in Lyme DiseaseNCT03769194 · 572 enrolled · United States, Belgium, Germany
- May 29, 2019Phase 2 study in Lyme DiseaseNCT03970733 · 246 enrolled · United States
- Mar 8, 2021Phase 2 study in Lyme DiseaseNCT04801420 · 625 enrolled · United States
- Jul 5, 2022Phase 3 study in Lyme DiseaseNCT05477524 · 12,546 enrolled · United States, Canada, Finland and more
- Nov 22, 2022Phase 3 study in Lyme DiseaseNCT05634811 · 3,547 enrolled · United States
- Oct 13, 2025Phase 3 study in Lyme DiseaseNCT07226882 · 207 enrolled · United States
- Mar 23, 2026Phase 3 study in Lyme DiseaseNCT07500506 · 1,712 planned · United States, Canada
Ahead
- Dec 4, 2026Primary completion: phase 3 study in Lyme DiseaseNCT07500506
- Jan 27, 2028Primary completion: phase 3 study in Lyme DiseaseNCT07226882
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Prophylactic vaccine – protein subunit (Lyme Disease)”the company's pipeline, read by Claude · source
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07500506Lyme Disease · United States, Canada | 3 | Recruiting | Dec 4, 2026 | 1,712 |
| NCT07226882Lyme Disease · United States | 3 | Active, not recruiting | Jan 27, 2028 | 207 |
| NCT05634811Lyme Disease · United States | 3 | Completed | Jul 21, 2025 | 3,547 |
| NCT05477524Lyme Disease · United States, Canada, Finland and more | 3 | Completed | Jan 7, 2026 | 12,546 |
| NCT04801420Lyme Disease · United States | 2 | Completed | Mar 25, 2022 | 625 |
| NCT03970733Lyme Disease · United States | 2 | Completed | Apr 7, 2020 | 246 |
| NCT03769194Lyme Disease · United States, Belgium, Germany | 2 | Completed | Dec 18, 2019 | 572 |
| NCT03010228Lyme Neuroborreliosis · United States, Belgium | 1 | Completed | Sep 28, 2017 | 179 |
How it is read
Names in the registry
- “VLA15”, 7 entries
- “VLA15 with Alum”, 1 entry
- “VLA15 without Alum”, 1 entry
Codes read as this program: VLA15.
Conditions, from the studies’ own filings
- Lyme Disease, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.